Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Series B | Dead

Total Raised


Last Raised


About VeloMedix

VeloMedix is a development stage medical device company created to realize the clinical potential of mild therapeutic hypothermia in benefiting patients suffering from ischemic and reperfusion injury effects of cardiac arrest, heart attack, stroke and traumatic brain injury.

VeloMedix Headquarters Location

1455 Adams Drive Suite 1016

Menlo Park, California, 94025,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

VeloMedix Patents

VeloMedix has filed 4 patents.

patents chart

Application Date

Grant Date


Related Topics




Medical treatments, Causes of death, Intensive care medicine, Cardiac arrhythmia, Abdomen


Application Date


Grant Date



Related Topics

Medical treatments, Causes of death, Intensive care medicine, Cardiac arrhythmia, Abdomen



Latest VeloMedix News

Jeffrey Gold Appointed Chief Executive Officer of myoscience

Nov 3, 2014

November 03, 2014 16:18 ET | Source: myoscience REDWOOD CITY, Calif., Nov. 3, 2014 (GLOBE NEWSWIRE) -- myoscience, inc. is pleased to announce the appointment of Jeffrey Gold as Chief Executive Officer (CEO) effective immediately. Mr. Gold, who previously held the position of President & COO, is an accomplished executive, having held posts as Chief Executive for Velomedix and CryoVascular Systems as well as Chief Operating Officer for CardioThoracic Systems. "I am very pleased to handover the role of Chief Executive Officer to Jeff Gold. Jeff is a seasoned executive with a solid record of success. The myoscience Board of Directors fully supports the appointment and we are excited to have Jeff accept the leadership role as CEO," said Rich Ferrari, myoscience Executive Chairman. Prior to joining myoscience, Mr. Gold was the President & CEO of Velomedix Inc, a venture backed company that developed a unique technology for rapidly inducing therapeutic hypothermia in patients undergoing severe acute cardiovascular events, such as heart attack and cardiac arrest. Prior to Velomedix, Mr. Gold was a Venture Partner for Longitude Capital where he focused on investments in medical devices. "I am very excited to assume the responsibility of guiding myoscience through its next development stage," said Gold. "The myoscience team has built an extremely strong platform technology that targets two distinct markets, aesthetics (for facial wrinkles) and peripheral nerve pain, both with tremendous potential. The patented iovera° product platform has demonstrated the ability to improve patients' lives in the aesthetics and pain management applications that is unmatched in those fields. We have a strong team of dedicated professionals that will drive myoscience to greater success in the future. " ABOUT MYOSCIENCE Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold TherapyTM, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the iovera° system. The iovera° system is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions, and is indicated in the United States for use in pain management and general surgical use. For more information, please visit . The myoscience logo is available at © 2014 myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of myoscience. MKT-0327 REV A MEDIA RELATIONSPeter Osborne / Related Articles other press releases by myoscience

  • Where is VeloMedix's headquarters?

    VeloMedix's headquarters is located at 1455 Adams Drive, Menlo Park.

  • What is VeloMedix's latest funding round?

    VeloMedix's latest funding round is Series B.

  • How much did VeloMedix raise?

    VeloMedix raised a total of $35.5M.

  • Who are the investors of VeloMedix?

    Investors of VeloMedix include Life Science Angels, Longitude Capital and Wavepoint Ventures.

  • Who are VeloMedix's competitors?

    Competitors of VeloMedix include Zogenix, BioCardia, Pearl Therapeutics, KAI Pharmaceuticals, AI2 and 10 more.

You May Also Like


Altheos, Inc. is an early-stage biopharmaceutical company focused on the identification and development of promising well-differentiated novel small molecule drugs for unmet medical needs. Altheos, Inc. was co-founded in 2009 by two experienced pharmaceutical drug development executives and entrepreneurs, Henry H. Hsu, M.D. and M. (Ken) Kengatharan, Ph.D. The company is headquartered in South San Francisco, California.


The company are developing siRNA drugs targeting a control factor for HIF (hypoxia-inducible factor), which is one of the main factors involved in angiogenesis. The company have found that siRNA can promote angiogenesis by inducing expression of several angiogenic factors simultaneously by preventing breakdown of HIF inside the cell. It is therefore expected that delivery of siRNA to disease-affected sites can efficiently induce angiogenesis, leading to a in treatment for obstructive arteriosclerosis.

Epiphany Biosciences

Epiphany Biosciences is focused on advancing new therapies for infectious disease. The founders include Fred Volinsky MD, Robert GalloMD, David Myles Ph.D and Barry Selick Ph.D. Epiphany is located in San Francisco, California.

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

ImaRx Therapeutics

We are a biopharmaceutical company developing and commercializing therapies for vascular disorders. Our research and development efforts are focused on therapies for stroke and other vascular disorders, using our proprietary microbubble technology to treat vascular occlusions, or blood vessel blockages, as well as the resulting ischemia, which is tissue damage caused by a reduced supply of oxygen.In addition to the brain and the lungs, blood clots can block blood flow and cause damage to other tissues in the body such as the heart, in case of coronary arterial disease, and the legs and other extremities, in case of peripheral vascular disease. We believe our development and research stage products may address significant unmet medical needs not only for stroke but also for clot-induced damage in tissues other than the brain.

Locus Pharmaceuticals

Locus Pharmaceuticals is a privately held pharmaceutical company focused on developing small molecule therapeutic drugs to address unmet medical needs. The company's core technology is a fragment-based, computational approach, which Locus has combinated with highly integrated medicinal chemistry, crystallography and biology capabilities to create a unique drug design and development platform.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.